Triple therapy in COPD: understanding the data

Effectiveness of single-inhaler triple therapy on exacerbation risk and mortality in COPD is exaggerated in IMPACT and ETHOS trials from confounding by prior ICS discontinuation: effectiveness fades in analyses and studies with no prior ICS discontinuation https://bit.ly/3tOgNdW

Detalles Bibliográficos
Autor principal: Suissa, Samy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Editorials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885273/
https://www.ncbi.nlm.nih.gov/pubmed/36726367
http://dx.doi.org/10.1183/23120541.00615-2022
Descripción
Sumario:Effectiveness of single-inhaler triple therapy on exacerbation risk and mortality in COPD is exaggerated in IMPACT and ETHOS trials from confounding by prior ICS discontinuation: effectiveness fades in analyses and studies with no prior ICS discontinuation https://bit.ly/3tOgNdW

Ejemplares similares